Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53

Background: Histone deacetylase (HDAC) inhibitors have emerged as a new class of anti-tumor agents for various types of tumors, including glioblastoma. Methods and results: We found that a novel HDAC inhibitor, MPT0B291, significantly reduced the cell viability and increased cell death of human and...

Descripción completa

Detalles Bibliográficos
Autores principales: Buyandelger, Batsaikhan, Bar, Eli E, Hung, Kuo-Sheng, Chen, Ruei-Ming, Chiang, Yung-Hsiao, Liou, Jing-Ping, Huang, Huei-Mei, Wang, Jia-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645997/
https://www.ncbi.nlm.nih.gov/pubmed/33162824
http://dx.doi.org/10.7150/ijbs.45505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645997/
https://www.ncbi.nlm.nih.gov/pubmed/33162824
http://dx.doi.org/10.7150/ijbs.45505

Ejemplares similares